熱門資訊> 正文
Mineralys Therapeutics推出1.75亿美元的公开募股
2025-09-03 04:17
- Mineralys Therapeutics (NASDAQ:MLYS) has commenced a $175M underwritten public offering of common stock.
- A 30-day option allows underwriters to purchase up to an additional $26.25M in shares.
- All shares in the offering will be sold by the company.
- Proceeds will support development of lorundrostat, a treatment for hypertension and related conditions, along with R&D, manufacturing, and corporate needs.
- MLYS shares down 3.4% post-market on Tuesday.
- Source: Press release
More on Mineralys Therapeutics
- Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript
- Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug
- Mineralys signals pre-NDA meeting for lorundrostat in Q4 2025 while expanding clinical programs into cardiorenal comorbidities
- Seeking Alpha’s Quant Rating on Mineralys Therapeutics
- Historical earnings data for Mineralys Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
